interesting post , page-3

Spoke to someone who consults in the pharma space and runs /structures trials for Biotechs. View s that BTA will need a significant amount of cash to pay out service providers ( I think CROs was the term ) who are likely to entered to contracts with BTA

Person was very surprised with the Barda contract termination, but their view is unlikely cash will remain at the same level and the expectation is a good chunk of it may need to be used

Please don't shoot the messenger, I really have no idea of BTas obligation and if this view is accurate but I thought it would only be fair to share as some may want to ask BTA management how much of the cash may be committed to contract obligations